Global Drug Repurposing Market

Drug Repurposing Comprehensive Study by Type (De novo drug discovery, Personalized Medicine, Genomics, Gene Editing), Application (Discovering drug targets,, Identifying and optimizing lead compounds,, Preclinical studies, and phase 1 through phase 4 clinical studies.), Methodology (Network-based approaches, Text mining approaches, Semantic approaches), Development Steps (Compound Identification, Compound Acquisition, Development, FDA Post Market safety monitoring) Players and Region - Global Market Outlook to 2028

Drug Repurposing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Overview:
In recent years, many pharmaceutical corporations are producing new medicines with the development of novel biological targets by applying the drug repositioning strategy in drug discovery and development program. Developing a new drug is costly and time-consuming and drug repurposing comes forth as an excellent alternative, Drug Repurposing act as recycling is the act of taking drug intended to treat one patient population and demonstrating its efficacy in the treatment of a completely different group of patients. This approach is very efficient, time-saving, low-cost and least risk of failure. It maximizes the healing value of medicine and consequently improves the success rate. Drug Repurposing is an effective strategy in discovering or developing drug molecules with new pharmacological/therapeutic indications. Thus, the rise in the demand for drug repurposing is used as an effective alternative approach to the traditional drug discovery process.



AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Key Companies ProfiledAstellas Pharma Inc.(Japan), Biovista(United States), Novartis AG(Switzerland), AbbVie Inc. (United States), Pfizer Inc. (United States), Allergan Plc. (Ireland), NuMedii (United States), Recursion Pharmaceuticals (United States), Leiden University Medical(Netherlands) and Linguamatics (United Kingdom)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region or narrow down segments in the final scope subject to feasibility


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics of major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Drug Repurposing Market Study:
Astellas Pharma Inc.(Japan), Biovista(United States), Novartis AG(Switzerland), AbbVie Inc. (United States), Pfizer Inc. (United States), Allergan Plc. (Ireland), NuMedii (United States), Recursion Pharmaceuticals (United States), Leiden University Medical(Netherlands) and Linguamatics (United Kingdom)

Drug Repurposing Market Segment Analysis
ScopeSub-Segments
Application / End Userdiscovering drug targets,, identifying and optimizing lead compounds, and preclinical studies, and phase 1 through phase 4 clinical studies.
TypeDe novo drug discovery, Personalized Medicine, Genomics and Gene Editing
Methodology Network-based approaches,Text mining approaches,Semantic approaches
Development StepsCompound Identification,Compound Acquisition,Development,FDA Post Market safety monitoring


Influencing Trend:
The research and funding support and Increasing market demand many pharmaceutical companies are developing new drugs or new therapeutic uses from existing/old/available drugs by drug repositioning approaches in less time, yet at low cost.

Market Growth Drivers:
The rise of repositioning with the increasing pharma involvement as development progresses and The need for the low investment in terms of time and money is fuelling demand for drug repurposing which is leading to the increasing number of pipeline products is propelling the growth of the drug repurposing market.

Challenges:
The challenges of the correct interpretation of existing pre-clinical/clinical evidence as well as the generation of new evidence concerning drug repurposing

Restraints:
Limited information is restraining the growth

Opportunities:
Drug Repurposing has several advantages in comparison with traditional approaches to drug discovery. When comparing with traditional drug discovery program, a significant reduction of the time spent in R&D can be observed and booming the growth opportunities

Some of the other players that are also part of study are FACULDADE DE CIENCIAS (Portugal), Advaita Bioinformatics (United States), Cyclica (United States) and Naama Barkai Lab (Israel). The Global Drug Repurposing market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Latest Industry Highlights:
In June 2020 C-Path launches Cure Drug Repurposing Collaboratory to treat infectious diseases, COVID-19. As millions of patients struggle with diseases that lack adequate treatments, there is a critical need to understand how existing drugs can be used in new ways to improve clinical outcomes. Health care professionals use drugs in novel ways as a potentially life-saving intervention when no specific approved therapies are available.
In December 2015,Biovista announced today that it has entered into a drug repositioning collaboration with Astellas Pharma Inc. The collaboration is focused on identifying new indications for a number of undisclosed Astellas compounds using Biovista's Clinical Outcome Search Space (COSS) technology.


Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Drug Repurposing market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Drug Repurposing market.
Identification of total players or companies operating in the global market which is further concentrated to fewer or most impacting players which are considered under the report’s scope. In order to make a priority list sorting is done based on revenue generated based on the latest reporting with the help of paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Drug Repurposing Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • De novo drug discovery
  • Personalized Medicine
  • Genomics
  • Gene Editing
By Application
  • discovering drug targets,
  • identifying and optimizing lead compounds,
  • preclinical studies, and phase 1 through phase 4 clinical studies.
By Methodology
  • Network-based approaches
  • Text mining approaches
  • Semantic approaches

By Development Steps
  • Compound Identification
  • Compound Acquisition
  • Development
  • FDA Post Market safety monitoring

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rise of repositioning with the increasing pharma involvement as development progresses
      • 3.2.2. The need for the low investment in terms of time and money is fuelling demand for drug repurposing which is leading to the increasing number of pipeline products is propelling the growth of the drug repurposing market.
    • 3.3. Market Challenges
      • 3.3.1. The challenges of the correct interpretation of existing pre-clinical/clinical evidence as well as the generation of new evidence concerning drug repurposing
    • 3.4. Market Trends
      • 3.4.1. The research and funding support
      • 3.4.2. Increasing market demand many pharmaceutical companies are developing new drugs or new therapeutic uses from existing/old/available drugs by drug repositioning approaches in less time, yet at low cost.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drug Repurposing, by Type, Application, Methodology , Development Steps and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Drug Repurposing (Value)
      • 5.2.1. Global Drug Repurposing by: Type (Value)
        • 5.2.1.1. De novo drug discovery
        • 5.2.1.2. Personalized Medicine
        • 5.2.1.3. Genomics
        • 5.2.1.4. Gene Editing
      • 5.2.2. Global Drug Repurposing by: Application (Value)
        • 5.2.2.1. Discovering drug targets,
        • 5.2.2.2. Identifying and optimizing lead compounds,
        • 5.2.2.3. Preclinical studies, and phase 1 through phase 4 clinical studies.
      • 5.2.3. Global Drug Repurposing by: Development Steps (Value)
        • 5.2.3.1. Compound Identification
        • 5.2.3.2. Compound Acquisition
        • 5.2.3.3. Development
        • 5.2.3.4. FDA Post Market safety monitoring
      • 5.2.4. Global Drug Repurposing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Drug Repurposing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astellas Pharma Inc.(Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Biovista(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG(Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AbbVie Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Allergan Plc. (Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. NuMedii (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Recursion Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Leiden University Medical(Netherlands)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Linguamatics (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drug Repurposing Sale, by Type, Application, Methodology , Development Steps and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Drug Repurposing (Value)
      • 7.2.1. Global Drug Repurposing by: Type (Value)
        • 7.2.1.1. De novo drug discovery
        • 7.2.1.2. Personalized Medicine
        • 7.2.1.3. Genomics
        • 7.2.1.4. Gene Editing
      • 7.2.2. Global Drug Repurposing by: Application (Value)
        • 7.2.2.1. Discovering drug targets,
        • 7.2.2.2. Identifying and optimizing lead compounds,
        • 7.2.2.3. Preclinical studies, and phase 1 through phase 4 clinical studies.
      • 7.2.3. Global Drug Repurposing by: Development Steps (Value)
        • 7.2.3.1. Compound Identification
        • 7.2.3.2. Compound Acquisition
        • 7.2.3.3. Development
        • 7.2.3.4. FDA Post Market safety monitoring
      • 7.2.4. Global Drug Repurposing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drug Repurposing: by Type(USD Million)
  • Table 2. Drug Repurposing De novo drug discovery , by Region USD Million (2017-2022)
  • Table 3. Drug Repurposing Personalized Medicine , by Region USD Million (2017-2022)
  • Table 4. Drug Repurposing Genomics , by Region USD Million (2017-2022)
  • Table 5. Drug Repurposing Gene Editing , by Region USD Million (2017-2022)
  • Table 6. Drug Repurposing: by Application(USD Million)
  • Table 7. Drug Repurposing Discovering drug targets, , by Region USD Million (2017-2022)
  • Table 8. Drug Repurposing Identifying and optimizing lead compounds, , by Region USD Million (2017-2022)
  • Table 9. Drug Repurposing Preclinical studies, and phase 1 through phase 4 clinical studies. , by Region USD Million (2017-2022)
  • Table 10. Drug Repurposing: by Development Steps(USD Million)
  • Table 11. Drug Repurposing Compound Identification , by Region USD Million (2017-2022)
  • Table 12. Drug Repurposing Compound Acquisition , by Region USD Million (2017-2022)
  • Table 13. Drug Repurposing Development , by Region USD Million (2017-2022)
  • Table 14. Drug Repurposing FDA Post Market safety monitoring , by Region USD Million (2017-2022)
  • Table 15. South America Drug Repurposing, by Country USD Million (2017-2022)
  • Table 16. South America Drug Repurposing, by Type USD Million (2017-2022)
  • Table 17. South America Drug Repurposing, by Application USD Million (2017-2022)
  • Table 18. South America Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 19. South America Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 20. Brazil Drug Repurposing, by Type USD Million (2017-2022)
  • Table 21. Brazil Drug Repurposing, by Application USD Million (2017-2022)
  • Table 22. Brazil Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 23. Brazil Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 24. Argentina Drug Repurposing, by Type USD Million (2017-2022)
  • Table 25. Argentina Drug Repurposing, by Application USD Million (2017-2022)
  • Table 26. Argentina Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 27. Argentina Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 28. Rest of South America Drug Repurposing, by Type USD Million (2017-2022)
  • Table 29. Rest of South America Drug Repurposing, by Application USD Million (2017-2022)
  • Table 30. Rest of South America Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 31. Rest of South America Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 32. Asia Pacific Drug Repurposing, by Country USD Million (2017-2022)
  • Table 33. Asia Pacific Drug Repurposing, by Type USD Million (2017-2022)
  • Table 34. Asia Pacific Drug Repurposing, by Application USD Million (2017-2022)
  • Table 35. Asia Pacific Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 36. Asia Pacific Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 37. China Drug Repurposing, by Type USD Million (2017-2022)
  • Table 38. China Drug Repurposing, by Application USD Million (2017-2022)
  • Table 39. China Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 40. China Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 41. Japan Drug Repurposing, by Type USD Million (2017-2022)
  • Table 42. Japan Drug Repurposing, by Application USD Million (2017-2022)
  • Table 43. Japan Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 44. Japan Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 45. India Drug Repurposing, by Type USD Million (2017-2022)
  • Table 46. India Drug Repurposing, by Application USD Million (2017-2022)
  • Table 47. India Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 48. India Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 49. South Korea Drug Repurposing, by Type USD Million (2017-2022)
  • Table 50. South Korea Drug Repurposing, by Application USD Million (2017-2022)
  • Table 51. South Korea Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 52. South Korea Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 53. Taiwan Drug Repurposing, by Type USD Million (2017-2022)
  • Table 54. Taiwan Drug Repurposing, by Application USD Million (2017-2022)
  • Table 55. Taiwan Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 56. Taiwan Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 57. Australia Drug Repurposing, by Type USD Million (2017-2022)
  • Table 58. Australia Drug Repurposing, by Application USD Million (2017-2022)
  • Table 59. Australia Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 60. Australia Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 61. Rest of Asia-Pacific Drug Repurposing, by Type USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Drug Repurposing, by Application USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 65. Europe Drug Repurposing, by Country USD Million (2017-2022)
  • Table 66. Europe Drug Repurposing, by Type USD Million (2017-2022)
  • Table 67. Europe Drug Repurposing, by Application USD Million (2017-2022)
  • Table 68. Europe Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 69. Europe Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 70. Germany Drug Repurposing, by Type USD Million (2017-2022)
  • Table 71. Germany Drug Repurposing, by Application USD Million (2017-2022)
  • Table 72. Germany Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 73. Germany Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 74. France Drug Repurposing, by Type USD Million (2017-2022)
  • Table 75. France Drug Repurposing, by Application USD Million (2017-2022)
  • Table 76. France Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 77. France Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 78. Italy Drug Repurposing, by Type USD Million (2017-2022)
  • Table 79. Italy Drug Repurposing, by Application USD Million (2017-2022)
  • Table 80. Italy Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 81. Italy Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 82. United Kingdom Drug Repurposing, by Type USD Million (2017-2022)
  • Table 83. United Kingdom Drug Repurposing, by Application USD Million (2017-2022)
  • Table 84. United Kingdom Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 85. United Kingdom Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 86. Netherlands Drug Repurposing, by Type USD Million (2017-2022)
  • Table 87. Netherlands Drug Repurposing, by Application USD Million (2017-2022)
  • Table 88. Netherlands Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 89. Netherlands Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 90. Rest of Europe Drug Repurposing, by Type USD Million (2017-2022)
  • Table 91. Rest of Europe Drug Repurposing, by Application USD Million (2017-2022)
  • Table 92. Rest of Europe Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 93. Rest of Europe Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 94. MEA Drug Repurposing, by Country USD Million (2017-2022)
  • Table 95. MEA Drug Repurposing, by Type USD Million (2017-2022)
  • Table 96. MEA Drug Repurposing, by Application USD Million (2017-2022)
  • Table 97. MEA Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 98. MEA Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 99. Middle East Drug Repurposing, by Type USD Million (2017-2022)
  • Table 100. Middle East Drug Repurposing, by Application USD Million (2017-2022)
  • Table 101. Middle East Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 102. Middle East Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 103. Africa Drug Repurposing, by Type USD Million (2017-2022)
  • Table 104. Africa Drug Repurposing, by Application USD Million (2017-2022)
  • Table 105. Africa Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 106. Africa Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 107. North America Drug Repurposing, by Country USD Million (2017-2022)
  • Table 108. North America Drug Repurposing, by Type USD Million (2017-2022)
  • Table 109. North America Drug Repurposing, by Application USD Million (2017-2022)
  • Table 110. North America Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 111. North America Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 112. United States Drug Repurposing, by Type USD Million (2017-2022)
  • Table 113. United States Drug Repurposing, by Application USD Million (2017-2022)
  • Table 114. United States Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 115. United States Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 116. Canada Drug Repurposing, by Type USD Million (2017-2022)
  • Table 117. Canada Drug Repurposing, by Application USD Million (2017-2022)
  • Table 118. Canada Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 119. Canada Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 120. Mexico Drug Repurposing, by Type USD Million (2017-2022)
  • Table 121. Mexico Drug Repurposing, by Application USD Million (2017-2022)
  • Table 122. Mexico Drug Repurposing, by Methodology USD Million (2017-2022)
  • Table 123. Mexico Drug Repurposing, by Development Steps USD Million (2017-2022)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Drug Repurposing: by Type(USD Million)
  • Table 135. Drug Repurposing De novo drug discovery , by Region USD Million (2023-2028)
  • Table 136. Drug Repurposing Personalized Medicine , by Region USD Million (2023-2028)
  • Table 137. Drug Repurposing Genomics , by Region USD Million (2023-2028)
  • Table 138. Drug Repurposing Gene Editing , by Region USD Million (2023-2028)
  • Table 139. Drug Repurposing: by Application(USD Million)
  • Table 140. Drug Repurposing Discovering drug targets, , by Region USD Million (2023-2028)
  • Table 141. Drug Repurposing Identifying and optimizing lead compounds, , by Region USD Million (2023-2028)
  • Table 142. Drug Repurposing Preclinical studies, and phase 1 through phase 4 clinical studies. , by Region USD Million (2023-2028)
  • Table 143. Drug Repurposing: by Development Steps(USD Million)
  • Table 144. Drug Repurposing Compound Identification , by Region USD Million (2023-2028)
  • Table 145. Drug Repurposing Compound Acquisition , by Region USD Million (2023-2028)
  • Table 146. Drug Repurposing Development , by Region USD Million (2023-2028)
  • Table 147. Drug Repurposing FDA Post Market safety monitoring , by Region USD Million (2023-2028)
  • Table 148. South America Drug Repurposing, by Country USD Million (2023-2028)
  • Table 149. South America Drug Repurposing, by Type USD Million (2023-2028)
  • Table 150. South America Drug Repurposing, by Application USD Million (2023-2028)
  • Table 151. South America Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 152. South America Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 153. Brazil Drug Repurposing, by Type USD Million (2023-2028)
  • Table 154. Brazil Drug Repurposing, by Application USD Million (2023-2028)
  • Table 155. Brazil Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 156. Brazil Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 157. Argentina Drug Repurposing, by Type USD Million (2023-2028)
  • Table 158. Argentina Drug Repurposing, by Application USD Million (2023-2028)
  • Table 159. Argentina Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 160. Argentina Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 161. Rest of South America Drug Repurposing, by Type USD Million (2023-2028)
  • Table 162. Rest of South America Drug Repurposing, by Application USD Million (2023-2028)
  • Table 163. Rest of South America Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 164. Rest of South America Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 165. Asia Pacific Drug Repurposing, by Country USD Million (2023-2028)
  • Table 166. Asia Pacific Drug Repurposing, by Type USD Million (2023-2028)
  • Table 167. Asia Pacific Drug Repurposing, by Application USD Million (2023-2028)
  • Table 168. Asia Pacific Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 169. Asia Pacific Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 170. China Drug Repurposing, by Type USD Million (2023-2028)
  • Table 171. China Drug Repurposing, by Application USD Million (2023-2028)
  • Table 172. China Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 173. China Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 174. Japan Drug Repurposing, by Type USD Million (2023-2028)
  • Table 175. Japan Drug Repurposing, by Application USD Million (2023-2028)
  • Table 176. Japan Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 177. Japan Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 178. India Drug Repurposing, by Type USD Million (2023-2028)
  • Table 179. India Drug Repurposing, by Application USD Million (2023-2028)
  • Table 180. India Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 181. India Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 182. South Korea Drug Repurposing, by Type USD Million (2023-2028)
  • Table 183. South Korea Drug Repurposing, by Application USD Million (2023-2028)
  • Table 184. South Korea Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 185. South Korea Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 186. Taiwan Drug Repurposing, by Type USD Million (2023-2028)
  • Table 187. Taiwan Drug Repurposing, by Application USD Million (2023-2028)
  • Table 188. Taiwan Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 189. Taiwan Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 190. Australia Drug Repurposing, by Type USD Million (2023-2028)
  • Table 191. Australia Drug Repurposing, by Application USD Million (2023-2028)
  • Table 192. Australia Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 193. Australia Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 194. Rest of Asia-Pacific Drug Repurposing, by Type USD Million (2023-2028)
  • Table 195. Rest of Asia-Pacific Drug Repurposing, by Application USD Million (2023-2028)
  • Table 196. Rest of Asia-Pacific Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 197. Rest of Asia-Pacific Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 198. Europe Drug Repurposing, by Country USD Million (2023-2028)
  • Table 199. Europe Drug Repurposing, by Type USD Million (2023-2028)
  • Table 200. Europe Drug Repurposing, by Application USD Million (2023-2028)
  • Table 201. Europe Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 202. Europe Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 203. Germany Drug Repurposing, by Type USD Million (2023-2028)
  • Table 204. Germany Drug Repurposing, by Application USD Million (2023-2028)
  • Table 205. Germany Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 206. Germany Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 207. France Drug Repurposing, by Type USD Million (2023-2028)
  • Table 208. France Drug Repurposing, by Application USD Million (2023-2028)
  • Table 209. France Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 210. France Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 211. Italy Drug Repurposing, by Type USD Million (2023-2028)
  • Table 212. Italy Drug Repurposing, by Application USD Million (2023-2028)
  • Table 213. Italy Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 214. Italy Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 215. United Kingdom Drug Repurposing, by Type USD Million (2023-2028)
  • Table 216. United Kingdom Drug Repurposing, by Application USD Million (2023-2028)
  • Table 217. United Kingdom Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 218. United Kingdom Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 219. Netherlands Drug Repurposing, by Type USD Million (2023-2028)
  • Table 220. Netherlands Drug Repurposing, by Application USD Million (2023-2028)
  • Table 221. Netherlands Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 222. Netherlands Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 223. Rest of Europe Drug Repurposing, by Type USD Million (2023-2028)
  • Table 224. Rest of Europe Drug Repurposing, by Application USD Million (2023-2028)
  • Table 225. Rest of Europe Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 226. Rest of Europe Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 227. MEA Drug Repurposing, by Country USD Million (2023-2028)
  • Table 228. MEA Drug Repurposing, by Type USD Million (2023-2028)
  • Table 229. MEA Drug Repurposing, by Application USD Million (2023-2028)
  • Table 230. MEA Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 231. MEA Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 232. Middle East Drug Repurposing, by Type USD Million (2023-2028)
  • Table 233. Middle East Drug Repurposing, by Application USD Million (2023-2028)
  • Table 234. Middle East Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 235. Middle East Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 236. Africa Drug Repurposing, by Type USD Million (2023-2028)
  • Table 237. Africa Drug Repurposing, by Application USD Million (2023-2028)
  • Table 238. Africa Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 239. Africa Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 240. North America Drug Repurposing, by Country USD Million (2023-2028)
  • Table 241. North America Drug Repurposing, by Type USD Million (2023-2028)
  • Table 242. North America Drug Repurposing, by Application USD Million (2023-2028)
  • Table 243. North America Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 244. North America Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 245. United States Drug Repurposing, by Type USD Million (2023-2028)
  • Table 246. United States Drug Repurposing, by Application USD Million (2023-2028)
  • Table 247. United States Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 248. United States Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 249. Canada Drug Repurposing, by Type USD Million (2023-2028)
  • Table 250. Canada Drug Repurposing, by Application USD Million (2023-2028)
  • Table 251. Canada Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 252. Canada Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 253. Mexico Drug Repurposing, by Type USD Million (2023-2028)
  • Table 254. Mexico Drug Repurposing, by Application USD Million (2023-2028)
  • Table 255. Mexico Drug Repurposing, by Methodology USD Million (2023-2028)
  • Table 256. Mexico Drug Repurposing, by Development Steps USD Million (2023-2028)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drug Repurposing: by Type USD Million (2017-2022)
  • Figure 5. Global Drug Repurposing: by Application USD Million (2017-2022)
  • Figure 6. Global Drug Repurposing: by Development Steps USD Million (2017-2022)
  • Figure 7. South America Drug Repurposing Share (%), by Country
  • Figure 8. Asia Pacific Drug Repurposing Share (%), by Country
  • Figure 9. Europe Drug Repurposing Share (%), by Country
  • Figure 10. MEA Drug Repurposing Share (%), by Country
  • Figure 11. North America Drug Repurposing Share (%), by Country
  • Figure 12. Global Drug Repurposing share by Players 2022 (%)
  • Figure 13. Global Drug Repurposing share by Players (Top 3) 2022(%)
  • Figure 14. Global Drug Repurposing share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Astellas Pharma Inc.(Japan) Revenue, Net Income and Gross profit
  • Figure 17. Astellas Pharma Inc.(Japan) Revenue: by Geography 2022
  • Figure 18. Biovista(United States) Revenue, Net Income and Gross profit
  • Figure 19. Biovista(United States) Revenue: by Geography 2022
  • Figure 20. Novartis AG(Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Novartis AG(Switzerland) Revenue: by Geography 2022
  • Figure 22. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. AbbVie Inc. (United States) Revenue: by Geography 2022
  • Figure 24. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 26. Allergan Plc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 27. Allergan Plc. (Ireland) Revenue: by Geography 2022
  • Figure 28. NuMedii (United States) Revenue, Net Income and Gross profit
  • Figure 29. NuMedii (United States) Revenue: by Geography 2022
  • Figure 30. Recursion Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 31. Recursion Pharmaceuticals (United States) Revenue: by Geography 2022
  • Figure 32. Leiden University Medical(Netherlands) Revenue, Net Income and Gross profit
  • Figure 33. Leiden University Medical(Netherlands) Revenue: by Geography 2022
  • Figure 34. Linguamatics (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Linguamatics (United Kingdom) Revenue: by Geography 2022
  • Figure 36. Global Drug Repurposing: by Type USD Million (2023-2028)
  • Figure 37. Global Drug Repurposing: by Application USD Million (2023-2028)
  • Figure 38. Global Drug Repurposing: by Development Steps USD Million (2023-2028)
  • Figure 39. South America Drug Repurposing Share (%), by Country
  • Figure 40. Asia Pacific Drug Repurposing Share (%), by Country
  • Figure 41. Europe Drug Repurposing Share (%), by Country
  • Figure 42. MEA Drug Repurposing Share (%), by Country
  • Figure 43. North America Drug Repurposing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Astellas Pharma Inc.(Japan)
  • Biovista(United States)
  • Novartis AG(Switzerland)
  • AbbVie Inc. (United States)
  • Pfizer Inc. (United States)
  • Allergan Plc. (Ireland)
  • NuMedii (United States)
  • Recursion Pharmaceuticals (United States)
  • Leiden University Medical(Netherlands)
  • Linguamatics (United Kingdom)
Additional players considered in the study are as follows:
FACULDADE DE CIENCIAS (Portugal) , Advaita Bioinformatics (United States) , Cyclica (United States) , Naama Barkai Lab (Israel)
Select User Access Type

Key Highlights of Report


Dec 2023 217 Pages 58 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drug Repurposing Market Quantitative research analysis
Global Drug Repurposing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"The research and funding support " is seen as one of major influencing trends for Drug Repurposing Market during projected period 2022-2028.
The Concentration Rate of Global Drug Repurposing market is highlighted using HHI Index.
United States Players will contribute the maximum growth of Global Drug Repurposing market throughout the predicted period.

Know More About Global Drug Repurposing Market Report?

Have a Query? Click Here

Other Related Reports

Cyclobenzaprine Comprehensive Study by Patient Type (Adult, Pediatric), Form (Tablet, Capsule), Distribution Channel (Hospitals & Clinics, Retail Pharmacies, Online Pharmacies), Dosage (5 mg, 7.5 mg,...
$ 3350
Pharmaceutical Contract Development and Manufacturing Comprehensive Study by Application (Big Pharma, Small & Mid-size Pharma, Generic Pharmaceutical Companies, Other End Users), Services (Pharmaceut...
$ 3750
Tablet Coatings Comprehensive Study by Type (Sugar Coating, Sealing, Sub Coating, Syrup Coating, Colouring, Polishing), Application (Nutraceuticals, Pharmaceuticals), Polymers (Cellulosic, Vinyl, Acr...
$ 3500
Ganirelix Comprehensive Study by Application (Infertility, Controlled Ovarian Stimulation, IVF Treatment, Premature Ovarian Failure (POF)), Form (Injection, Solution), Packaging (Single syringe, Box ...
$ 3650
Carisoprodol Tablets Comprehensive Study by Type (Carisoprodol 250 mg Tablet, Carisoprodol 350 mg Tablet), End-users (Hospitals, Clinics, Others), Distribution Channel (Hospital Pharmacies, Retail Ph...
$ 3350
Disclosing Tablets Comprehensive Study by Composition (Erythrosine, Fluorescein, Iodine), Ager group (Children, Adults, Geriatric Population), Distribution Channel (Online, Medical Stores, Pharmacies...
$ 3450